Biodissimilars

Extended discussion about follow-on biologics in both houses of Congress last week made it perfectly clear that there is unanimity regarding the wisdom of creating a pathway for FOBs. But there is nearly complete disagreement about how to go about it.

It is clear the only way FOBs legislation will be enacted by the 110th Congress is if it is perceived as protecting the interests of innovators, as senators and representatives who strongly favor the interests of generic drug companies are finding themselves unable to advance their biogenerics proposals. ...